Pathway analyses using ingenuity pathway analysis (IPA) predicted that MARK3 overexpression resulted in the reduced activity of oncogenes such as MYC, ESR1, KRAS, and VEGF, as well as the elevated activity of tumor suppressor genes such as PTEN, CDKN1A, and CDKN2A, supporting the tumor-suppressive roles of MARK3 (Supplementary Data 1). The gene discussed is ESR1; the disease is neoplasm.